These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 8738671)
21. Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival. Hariharan S; Alexander JW; Schroeder TJ; First MR Clin Transplant; 1996 Dec; 10(6 Pt 1):538-41. PubMed ID: 8996775 [TBL] [Abstract][Full Text] [Related]
22. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061 [TBL] [Abstract][Full Text] [Related]
23. Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. Budde K; Fritsche L; Mai I; Bauer S; Smettan S; Waiser J; Hofmann T; Hauser I; Reinke P; Neumayer HH Int J Clin Pharmacol Ther; 1996 Nov; 34(11):493-7. PubMed ID: 8937932 [TBL] [Abstract][Full Text] [Related]
24. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure. Waid T; Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546 [TBL] [Abstract][Full Text] [Related]
25. Use of tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. Peddi VR; Kamath S; Munda R; Demmy AM; Alexander JW; First MR Clin Transplant; 1998 Oct; 12(5):401-5. PubMed ID: 9787948 [TBL] [Abstract][Full Text] [Related]
26. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. Kim HC; Hwang EA; Han SY; Park SB; Kim HT; Cho WH Transplant Proc; 2004 Sep; 36(7):2082-3. PubMed ID: 15518753 [TBL] [Abstract][Full Text] [Related]
28. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients. Herzberg GZ; Rossi AF; Courtney M; Gelb BD J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760 [TBL] [Abstract][Full Text] [Related]
29. Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation. Pascher A; Radke C; Dignass A; Schulz RJ; Veltzke-Schlieker W; Adler A; Sauer IM; Platz K; Klupp J; Volk HD; Neuhaus P; Mueller AR Transplantation; 2003 Aug; 76(3):615-8. PubMed ID: 12923454 [TBL] [Abstract][Full Text] [Related]
30. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. Kliem V; Eberhard OK; Oldhafer K; Schlitt HJ; Behrend M; Schaumann D; Pichlmayr R; Koch KM; Brunkhorst R Transplant Proc; 1996 Dec; 28(6):3166-8. PubMed ID: 8962227 [No Abstract] [Full Text] [Related]
31. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation? Wagner FM; Reichenspurner H; Uberfuhr P; Kur F; Kaulbach HG; Meiser BM; Ziegler U; Reichart B J Heart Lung Transplant; 1994; 13(3):438-42; discussion 442-3. PubMed ID: 8061020 [TBL] [Abstract][Full Text] [Related]
32. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163 [TBL] [Abstract][Full Text] [Related]
33. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients. Kumano K; Irie A; Mashimo S; Endo T; Koshiba K Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691 [No Abstract] [Full Text] [Related]
34. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients. McKee M; Segev D; Wise B; Case B; Neu A; Fivush B; Colombani P J Pediatr Surg; 1997 May; 32(5):688-90. PubMed ID: 9165452 [TBL] [Abstract][Full Text] [Related]
35. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. Horning NR; Lynch JP; Sundaresan SR; Patterson GA; Trulock EP J Heart Lung Transplant; 1998 Aug; 17(8):761-7. PubMed ID: 9730424 [TBL] [Abstract][Full Text] [Related]
36. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. Bahra M; Neumann UP; Jacob D; Langrehr JM; Neuhaus P Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436 [TBL] [Abstract][Full Text] [Related]
37. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. Ciancio G; Carreno M; Mathew J; Ricordi C; Garcia R; Karatzas T; Fuller L; Cirocco R; Burke G; Webb M; Nery J; Tzakis A; Roth D; Esquenazi V; Miller J Transplant Proc; 1996 Apr; 28(2):943-4. PubMed ID: 8623473 [No Abstract] [Full Text] [Related]
38. Experimental and clinical experience with the use of tacrolimus (FK506) in kidney transplantation. Wagner K; Herget S; Heemann U Clin Nephrol; 1996 May; 45(5):332-5. PubMed ID: 8738666 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation. Shennib H; Massard G; Reynaud M; Noirclerc M J Heart Lung Transplant; 1994; 13(3):514-9. PubMed ID: 8061029 [TBL] [Abstract][Full Text] [Related]
40. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3? Dé P; Bechstein WO; Blumhardt G; Lange D; Schattenfroh N; Neuhaus P Transplant Proc; 1993 Aug; 25(4):2693-4. PubMed ID: 7689279 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]